BioCentury
ARTICLE | Emerging Company Profile

Teasing out Th1

EpiThany's strategy for creating more potent therapeutic cancer vaccines

August 18, 2017 4:53 PM UTC

EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation.

Like most cancer vaccines in development, EpiThany's deliver self-antigens -- pieces of proteins normally found in the body but produced at much higher levels in tumor cells than in healthy cells...

BCIQ Company Profiles

EpiThany Inc.